Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
Analysts Set New Price Targets
Separately, HC Wainwright lowered their price objective on shares of Vyant Bio to $3.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th.
Vyant Bio Price Performance
Shares of NASDAQ:VYNT traded up $0.01 during midday trading on Friday, hitting $0.82. 18,881 shares of the company traded hands, compared to its average volume of 27,888. Vyant Bio has a 12-month low of $0.60 and a 12-month high of $3.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.74 and a quick ratio of 2.67. The stock has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.95.
Vyant Bio (NASDAQ:VYNT - Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.30 million. On average, equities research analysts forecast that Vyant Bio will post -0.56 earnings per share for the current fiscal year.